Cargando…

Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers

BACKGROUND: Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratschke, Sebastian, Arnold, Hannah, Zollner, Alfred, Heise, Michael, Pascher, Andreas, Schemmer, Peter, Scherer, Marcus N., Bauer, Andreas, Jauch, Karl-Walter, Werner, Jens, Guba, Markus, Angele, Martin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946517/
https://www.ncbi.nlm.nih.gov/pubmed/27500266
http://dx.doi.org/10.1097/TXD.0000000000000588
_version_ 1782443038465851392
author Pratschke, Sebastian
Arnold, Hannah
Zollner, Alfred
Heise, Michael
Pascher, Andreas
Schemmer, Peter
Scherer, Marcus N.
Bauer, Andreas
Jauch, Karl-Walter
Werner, Jens
Guba, Markus
Angele, Martin K.
author_facet Pratschke, Sebastian
Arnold, Hannah
Zollner, Alfred
Heise, Michael
Pascher, Andreas
Schemmer, Peter
Scherer, Marcus N.
Bauer, Andreas
Jauch, Karl-Walter
Werner, Jens
Guba, Markus
Angele, Martin K.
author_sort Pratschke, Sebastian
collection PubMed
description BACKGROUND: Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI. The tacrolimus organ perfusion study was initiated to examine the effects of ex vivo tacrolimus perfusion on IRI in transplantation of EDC livers. METHODS: A prospective randomized multicenter trial comparing ex vivo perfusion of marginal liver grafts (≥2 EDC according to Eurotransplant manual) with tacrolimus (20 ng/mL) or histidine-tryptophane-ketoglutarate solution (control) was carried out at 5 German liver transplant centers (Munich Ludwig-Maximilians University, Berlin, Heidelberg, Mainz, Regensburg) between October 2011 and July 2013. Primary endpoint was the maximum alanine transaminase (ALT) level within 48 hours after transplantation. Secondary endpoints were aspartate transaminase (AST), prothrombine ratio, and graft-patient survival within an observation period of 1 week. After an interim analysis, the study was terminated by the scientific committee after the treatment of 24 patients (tacrolimus n = 11, Control n = 13). RESULTS: Tacrolimus rinse did not reduce postoperative ALT peaks compared with control (P = 0.207; tacrolimus: median, 812; range, 362-3403 vs control: median, 652; range, 147-2034). Moreover, ALT (P = 0.100), prothrombine ratio (P = 0.553), and bilirubin (P = 0.815) did not differ between the groups. AST was higher in patients treated with tacrolimus (P = 0.011). Survival was comparable in both groups (P > 0.05). CONCLUSIONS: Contrary to experimental findings, tacrolimus rinse failed to improve the primary endpoint of the study (ALT). Because 1 secondary endpoint (AST) was even higher in the intervention group, the study was terminated prematurely. Thus, tacrolimus rinse cannot be recommended in transplantation of EDC livers.
format Online
Article
Text
id pubmed-4946517
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-49465172016-08-05 Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers Pratschke, Sebastian Arnold, Hannah Zollner, Alfred Heise, Michael Pascher, Andreas Schemmer, Peter Scherer, Marcus N. Bauer, Andreas Jauch, Karl-Walter Werner, Jens Guba, Markus Angele, Martin K. Transplant Direct Liver Transplantation BACKGROUND: Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI. The tacrolimus organ perfusion study was initiated to examine the effects of ex vivo tacrolimus perfusion on IRI in transplantation of EDC livers. METHODS: A prospective randomized multicenter trial comparing ex vivo perfusion of marginal liver grafts (≥2 EDC according to Eurotransplant manual) with tacrolimus (20 ng/mL) or histidine-tryptophane-ketoglutarate solution (control) was carried out at 5 German liver transplant centers (Munich Ludwig-Maximilians University, Berlin, Heidelberg, Mainz, Regensburg) between October 2011 and July 2013. Primary endpoint was the maximum alanine transaminase (ALT) level within 48 hours after transplantation. Secondary endpoints were aspartate transaminase (AST), prothrombine ratio, and graft-patient survival within an observation period of 1 week. After an interim analysis, the study was terminated by the scientific committee after the treatment of 24 patients (tacrolimus n = 11, Control n = 13). RESULTS: Tacrolimus rinse did not reduce postoperative ALT peaks compared with control (P = 0.207; tacrolimus: median, 812; range, 362-3403 vs control: median, 652; range, 147-2034). Moreover, ALT (P = 0.100), prothrombine ratio (P = 0.553), and bilirubin (P = 0.815) did not differ between the groups. AST was higher in patients treated with tacrolimus (P = 0.011). Survival was comparable in both groups (P > 0.05). CONCLUSIONS: Contrary to experimental findings, tacrolimus rinse failed to improve the primary endpoint of the study (ALT). Because 1 secondary endpoint (AST) was even higher in the intervention group, the study was terminated prematurely. Thus, tacrolimus rinse cannot be recommended in transplantation of EDC livers. Lippincott Williams & Wilkins 2016-05-04 /pmc/articles/PMC4946517/ /pubmed/27500266 http://dx.doi.org/10.1097/TXD.0000000000000588 Text en Copyright © 2016 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Liver Transplantation
Pratschke, Sebastian
Arnold, Hannah
Zollner, Alfred
Heise, Michael
Pascher, Andreas
Schemmer, Peter
Scherer, Marcus N.
Bauer, Andreas
Jauch, Karl-Walter
Werner, Jens
Guba, Markus
Angele, Martin K.
Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers
title Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers
title_full Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers
title_fullStr Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers
title_full_unstemmed Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers
title_short Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers
title_sort results of the top study: prospectively randomized multicenter trial of an ex vivo tacrolimus rinse before transplantation in edc livers
topic Liver Transplantation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946517/
https://www.ncbi.nlm.nih.gov/pubmed/27500266
http://dx.doi.org/10.1097/TXD.0000000000000588
work_keys_str_mv AT pratschkesebastian resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT arnoldhannah resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT zollneralfred resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT heisemichael resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT pascherandreas resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT schemmerpeter resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT scherermarcusn resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT bauerandreas resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT jauchkarlwalter resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT wernerjens resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT gubamarkus resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers
AT angelemartink resultsofthetopstudyprospectivelyrandomizedmulticentertrialofanexvivotacrolimusrinsebeforetransplantationinedclivers